Payment overview · 2025
General Payments
$2,279.55
108 reported records · 21 companies
Healthcare provider profile · identity verified
Jinping Chai, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ARLINGTON, TX · NPI 1952341265
Verified facts
What the public records show
CMS Open Payments records show Jinping Chai, MD received $2,279.55 in general payments during 2025 across 108 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Qulipta, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $436.07 | 19.1% | 14 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $367.92 | 16.1% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $244.74 | 10.7% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $205.59 | 9.0% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $176.70 | 7.8% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $174.36 | 7.7% | 14 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $122.37 | 5.4% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $98.60 | 4.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.35 | 3.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.81 | 3.2% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.96 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.69 | 2.4% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $28.47 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.71 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.52 | 1.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.08 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.08 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.74 | 0.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.50 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.20 | 0.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.09 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,279.55 | 108 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $244.74 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $205.20 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $189.07 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $179.28 | 11 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $176.70 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $137.03 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $135.71 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $133.43 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $122.37 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.25 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $105.48 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $98.60 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $97.31 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.81 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.28 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.01 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $61.49 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $61.49 | 4 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $55.96 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.69 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $52.93 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $28.47 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $27.71 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.07 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.86 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 40 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 133 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 24 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
133 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
32 | 31 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
40 | 16 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 683 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 571 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 531 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 474 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 462 | 153 |
| Losartan Potassium | Losartan Potassium | 346 | 105 |
| Montelukast Sodium | Montelukast Sodium | 331 | 107 |
| Gabapentin | Gabapentin | 303 | 99 |
| Furosemide | Furosemide | 269 | 97 |
| Metformin Hcl | Metformin Hcl | 257 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 80 |
| Lisinopril | Lisinopril | 244 | 73 |
| Tramadol Hcl | Tramadol Hcl | 238 | 77 |
| Potassium Chloride | Potassium Chloride | 213 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 203 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 201 | 54 |
| Omeprazole | Omeprazole | 200 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 196 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 192 | 79 |
| Carvedilol | Carvedilol | 189 | 47 |
| Azithromycin | Azithromycin | 187 | 129 |
| Alendronate Sodium | Alendronate Sodium | 177 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 171 | 46 |
| Estradiol | Estradiol | 168 | 67 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 164 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 159 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 52 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 144 | 103 |
| Sertraline Hcl | Sertraline Hcl | 143 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 44 |
| Eliquis | Apixaban | 142 | 40 |
| Trazodone Hcl | Trazodone Hcl | 141 | 47 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 137 | 48 |
| Doxycycline Hyclate | Doxycycline Hyclate | 136 | 98 |
| Meloxicam | Meloxicam | 135 | 60 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 132 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 56 |
| Bupropion Xl | Bupropion Hcl | 125 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 119 | 36 |
| Ezetimibe | Ezetimibe | 116 | 42 |
| Prednisone | Prednisone | 108 | 75 |
| Mirtazapine | Mirtazapine | 106 | 36 |
| Ondansetron Odt | Ondansetron | 106 | 51 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 31 |
| Buspirone Hcl | Buspirone Hcl | 102 | 39 |
| Simvastatin | Simvastatin | 102 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 18 |
| Donepezil Hcl | Donepezil Hcl | 93 | 23 |
| Clonazepam | Clonazepam | 89 | 16 |
| Finasteride | Finasteride | 85 | 29 |
| Synthroid | Levothyroxine Sodium | 85 | 24 |
| Ozempic | Semaglutide | 84 | 23 |
| Glipizide Er | Glipizide | 83 | 23 |
| Telmisartan | Telmisartan | 82 | 23 |
| Eszopiclone | Eszopiclone | 80 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 27 |
| Nifedipine Er | Nifedipine | 80 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 44 |
| Methocarbamol | Methocarbamol | 79 | 33 |
| Raloxifene Hcl | Raloxifene Hcl | 78 | 22 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 78 | 20 |
| Allopurinol | Allopurinol | 75 | 23 |
| Farxiga | Dapagliflozin Propanediol | 75 | 23 |
| Rivastigmine | Rivastigmine Tartrate | 72 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 22 |
| Azelastine Hcl | Azelastine Hcl | 68 | 29 |
| Famotidine | Famotidine | 68 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 68 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 52 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | 22 |
| Jardiance | Empagliflozin | 59 | 19 |
| Cefdinir | Cefdinir | 58 | 47 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 15 |
| Memantine Hcl | Memantine Hcl | 55 | 12 |
| Metronidazole | Metronidazole | 55 | 45 |
| Methylprednisolone | Methylprednisolone | 54 | 46 |
| Pregabalin | Pregabalin | 54 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 54 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 51 | 23 |
| Levetiracetam | Levetiracetam | 51 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 15 |
| Januvia | Sitagliptin Phosphate | 48 | 12 |
| Temazepam | Temazepam | 47 | 12 |
| Celecoxib | Celecoxib | 45 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 45 | 18 |
| Atenolol | Atenolol | 44 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 37 |
| Myrbetriq | Mirabegron | 44 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 13 |
| Metformin Hcl Er | Metformin Hcl | 42 | 14 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 18 |
| Gemtesa | Vibegron | 40 | 16 |
| Spironolactone | Spironolactone | 39 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 38 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Trimethoprim | Trimethoprim | 35 | 13 |
| Clonidine Hcl | Clonidine Hcl | 34 | 15 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | 13 |
| Alprazolam | Alprazolam | 33 | 16 |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | 12 |
| Valacyclovir | Valacyclovir Hcl | 33 | 18 |
| Amoxicillin | Amoxicillin | 32 | 29 |
| Paxlovid | Nirmatrelvir/Ritonavir | 32 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | 11 |
| Nystatin | Nystatin | 29 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 12 |
| Glipizide | Glipizide | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Topiramate | Topiramate | 24 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 20 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 11 |
| Minoxidil | Minoxidil | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 16 |
| Linzess | Linaclotide | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,279.55 · 108 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, GIVLAARI, HYQVIA, JARDIANCE, Kerendia, LINZESS, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VRAYLAR, Veozah, ZEPBOUND, ZORYVE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error